[go: up one dir, main page]

NO20016221L - Difosfatsalt av et 4"-substituert-9-deokso-9A-aza-9A- homoerytromycinderivat og farmasöytisk preparat derav - Google Patents

Difosfatsalt av et 4"-substituert-9-deokso-9A-aza-9A- homoerytromycinderivat og farmasöytisk preparat derav

Info

Publication number
NO20016221L
NO20016221L NO20016221A NO20016221A NO20016221L NO 20016221 L NO20016221 L NO 20016221L NO 20016221 A NO20016221 A NO 20016221A NO 20016221 A NO20016221 A NO 20016221A NO 20016221 L NO20016221 L NO 20016221L
Authority
NO
Norway
Prior art keywords
mammals
diphosphate salt
methyl
free base
diphosphate
Prior art date
Application number
NO20016221A
Other languages
English (en)
Other versions
NO20016221D0 (no
Inventor
Robert John Rafka
Colman Brendan Ragan
Douglas John Meldrum Allen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20016221D0 publication Critical patent/NO20016221D0/no
Publication of NO20016221L publication Critical patent/NO20016221L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Denne oppfinnelse vedrører et nytt, krystallinsk difosfatsalt av. (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoksy-3-C-metyl-3-0-metyl-4-C-[(propylamino)metyl]-a-L-ribo-heksopryanosyl]oksy]-2-etyl-3,4,10-trihydroksy-3,5,8,10,12J4-heksametyl-11-[[3,4,6-trideoksy-3-(dimetylamino)-p-D-xylo-hekso-pyranosyl]oksy]-1-oksa-6-azacyklopentadekan-15-on som er nyttig som et. antibakterielt og antiprotozo-middel til pattedyr. Denne oppfinnelse vedrører også farmasøytiske preparater som inneholder den frie base av difosfatsaltet og frem-gangsmåtene for behandling av bakterielle og protozo-infeksjoner i pattedyr, ved administrering av den frie base av difosfatet til pattedyr som har behov for slik behandling. Den frie base av difosfatsaltet ifølge foreliggende oppfinnelse er i besit-telse av kraftig aktivitet mot forskjellige bakterielle og protozo-infeksjoner når de gis ved parenteral anvendelse til pattedyr.
NO20016221A 1999-06-30 2001-12-19 Difosfatsalt av et 4"-substituert-9-deokso-9A-aza-9A- homoerytromycinderivat og farmasöytisk preparat derav NO20016221L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14168199P 1999-06-30 1999-06-30
PCT/IB2000/000785 WO2001002414A1 (en) 1999-06-30 2000-06-13 Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO20016221D0 NO20016221D0 (no) 2001-12-19
NO20016221L true NO20016221L (no) 2001-12-19

Family

ID=22496734

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016221A NO20016221L (no) 1999-06-30 2001-12-19 Difosfatsalt av et 4"-substituert-9-deokso-9A-aza-9A- homoerytromycinderivat og farmasöytisk preparat derav

Country Status (42)

Country Link
US (3) US6465437B1 (no)
EP (1) EP1189913B1 (no)
JP (1) JP2003503506A (no)
KR (1) KR100442508B1 (no)
CN (2) CN101220067A (no)
AP (1) AP2001002370A0 (no)
AR (1) AR035551A1 (no)
AT (1) ATE286906T1 (no)
AU (1) AU772277B2 (no)
BG (1) BG65587B1 (no)
BR (1) BR0012091A (no)
CA (1) CA2376748C (no)
CO (1) CO5190679A1 (no)
CZ (1) CZ20014571A3 (no)
DE (1) DE60017399T2 (no)
EA (1) EA004235B1 (no)
EC (1) ECSP003555A (no)
EE (1) EE05068B1 (no)
ES (1) ES2233380T3 (no)
GT (2) GT200000105AA (no)
HN (1) HN2000000090A (no)
HR (1) HRP20010919B1 (no)
HU (1) HUP0201693A3 (no)
IL (1) IL146408A0 (no)
IS (1) IS6159A (no)
MA (1) MA26745A1 (no)
MX (1) MXPA02000058A (no)
MY (1) MY133360A (no)
NO (1) NO20016221L (no)
OA (1) OA11965A (no)
PA (1) PA8496901A1 (no)
PE (1) PE20010287A1 (no)
PL (1) PL201891B1 (no)
PT (1) PT1189913E (no)
SK (1) SK286243B6 (no)
TN (1) TNSN00143A1 (no)
TR (1) TR200103834T2 (no)
UA (1) UA71013C2 (no)
UY (1) UY26221A1 (no)
WO (1) WO2001002414A1 (no)
YU (1) YU88701A (no)
ZA (1) ZA200110453B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) * 2002-02-12 2004-09-14 Seiko Epson Corporation Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2013013834A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN110885351A (zh) * 2019-12-17 2020-03-17 海门慧聚药业有限公司 泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
EA003417B1 (ru) * 1999-05-18 2003-04-24 Пфайзер Продактс Инк. Новые кристаллические формы макролидного антибиотика
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Also Published As

Publication number Publication date
GT200000105A (es) 2001-12-20
HRP20010919A2 (en) 2003-02-28
ATE286906T1 (de) 2005-01-15
HUP0201693A2 (en) 2002-10-28
CN101220067A (zh) 2008-07-16
SK286243B6 (sk) 2008-06-06
BG65587B1 (bg) 2009-01-30
NO20016221D0 (no) 2001-12-19
HRP20010919B1 (en) 2005-06-30
HUP0201693A3 (en) 2003-03-28
UY26221A1 (es) 2001-01-31
JP2003503506A (ja) 2003-01-28
KR20020016875A (ko) 2002-03-06
CZ20014571A3 (cs) 2002-04-17
US20040209826A1 (en) 2004-10-21
US20030092642A1 (en) 2003-05-15
US7297682B2 (en) 2007-11-20
HN2000000090A (es) 2001-04-20
EA004235B1 (ru) 2004-02-26
BR0012091A (pt) 2002-04-02
KR100442508B1 (ko) 2004-07-30
GT200000105AA (es) 2001-12-20
IS6159A (is) 2001-11-13
PA8496901A1 (es) 2002-08-26
UA71013C2 (uk) 2004-11-15
US6861412B2 (en) 2005-03-01
EP1189913B1 (en) 2005-01-12
BG106123A (en) 2002-05-31
DE60017399T2 (de) 2006-03-30
EE200100699A (et) 2003-02-17
PL352900A1 (en) 2003-09-22
DE60017399D1 (de) 2005-02-17
YU88701A (sh) 2004-09-03
SK18922001A3 (sk) 2002-04-04
CA2376748C (en) 2006-03-14
EE05068B1 (et) 2008-08-15
US6465437B1 (en) 2002-10-15
PL201891B1 (pl) 2009-05-29
WO2001002414A1 (en) 2001-01-11
ECSP003555A (es) 2002-01-25
ES2233380T3 (es) 2005-06-16
CN1358188A (zh) 2002-07-10
AU4943900A (en) 2001-01-22
TR200103834T2 (tr) 2002-05-21
MY133360A (en) 2007-11-30
AR035551A1 (es) 2004-06-16
OA11965A (en) 2006-04-12
EA200101178A1 (ru) 2002-06-27
MXPA02000058A (es) 2002-07-02
AU772277B2 (en) 2004-04-22
MA26745A1 (fr) 2004-12-20
TNSN00143A1 (fr) 2005-11-10
PT1189913E (pt) 2005-04-29
ZA200110453B (en) 2003-03-04
PE20010287A1 (es) 2001-03-05
CO5190679A1 (es) 2002-08-29
EP1189913A1 (en) 2002-03-27
CA2376748A1 (en) 2001-01-11
IL146408A0 (en) 2002-07-25
AP2001002370A0 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
WO2003004509A3 (en) C12 modified erythromycin macrolides and ketolides having antibacterial activity
PT952835E (pt) Metodo de tratamento de doenca cardiaca causada por chlamidia pneumoniae
US4640910A (en) Erythromycin A silylated compounds and method of use
CA2316919A1 (en) Novel macrolides
KR20050003455A (ko) 6-11 비시클릭 케토리드 유도체
JPS61251696A (ja) 新規化合物，その製法及びそれを含む医薬組成物
NO20016221L (no) Difosfatsalt av et 4"-substituert-9-deokso-9A-aza-9A- homoerytromycinderivat og farmasöytisk preparat derav
EP0222186B1 (en) Erythromycin derivatives /a
CA2483875A1 (en) 6,11 bicyclic erythromycin derivatives
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates
ES2254389T3 (es) Agentes anti-infecciosos utiles contra cepas bacterianas resistntes a multiples farmacos.
JP3631510B2 (ja) 細菌バイオフィルム形成阻害剤
HUP0102412A2 (hu) 2"-Dezoxi-higromicin-származékok
WO2004108746A3 (en) 11-12 bicyclic erythromycin derivatives
WO2004000864A3 (en) 11-c-substituted ketolides
MXPA04010557A (es) Antibacterianos de 11-deoxi azalide.
HUP0203223A2 (en) Hygromycin a prodrugs
WO2004108745A3 (en) 11-12 bicyclic erythromycin derivatives
WO2017122146A1 (en) Pharmaceutical compositions for the treatment of bacterial infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application